How to avoid “growth traps”
When high-growth stocks stumble, the market reaction can be brutal. And there’s plenty more to come, says John Stepek.


Most investors have heard the term “value trap”. Indeed, if you’re a value-inclined investor, you’ve probably heard it rather more often than you’d like over the last few years. A value trap is a stock that looks cheap (usually based on a “fundamental” measure such as the price/book ratio) and ripe for a turnaround at any minute, but which simply keeps underperforming. Value traps can do a lot of harm to a portfolio and they are plentiful, says Ben Inker of US asset manager GMO. Inker defines a “trap” as a stock which has missed its revenue expectations in the past 12 months and has also warned on its future sales outlook. In a typical year, nearly a third of the stocks in the MSCI USA value index turn out to be value traps. On average they underperform the index by 9%. So it’s easy to see why the term is so well known. Investors are far less familiar with the idea of a “growth trap”.
A growth trap is just a growth stock (a stock which looks expensive but appears to be growing rapidly enough to justify the premium valuation) which misses its forecasts in the same way. These are, says Inker, even more common and even more damaging than value traps. In any given year, about 37% of the MSCI USA Growth index fall into the category, with an average underperformance of 13%. A good recent example is Snap, which owns social media app Snapchat. Snap saw its share price drop by about 45% in a day last week, after it warned that advertising revenue would be at the lower end of expectations and that the outlook for the wider economy was deteriorating rapidly. The stock is now down about 85% on its 2021 peak.
You can see why “growth traps” are more painful than “value traps”. When a value stock disappoints, it’s just underperforming already low expectations. But when a former growth star disappoints, the gap between the dream and the reality is far greater – so prices have to fall sharply to adjust. Snap is far from the only “growth trap” to have sprung shut in the past year or so. Rising interest rates and the end of the pandemic have made for a particularly tough backdrop for high-flying companies. Streaming service Netflix, crypto exchange Coinbase and fancy exercise bike company Peloton are just some of the casualties.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Yet for those thinking of going bargain hunting, Inker notes that – while they’ve started to lose some of their premium rating – growth stocks remain very expensive relative to value stocks compared to history. That in turn implies, he says, that we can expect to see more “growth trap” collapses “in the next year than there were in the last one”. In other words, remain wary of expensive stocks that are still pricing in lots of growth – and hang on to your value stocks.
For more on the topic, see:
Value is starting to emerge in the markets
Has growth investing had its day? Don’t be so sure
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.
He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.
His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine Published
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves Published